Rituximab done: What's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 55, Issue 2, 2015, Pages 230-236

  Walker, Ulrich A ^a   Jaeger, Veronika K ^a   Chatzidionysiou, Katerina ^b   Hetland, Merete L ^c,d   Hauge, Ellen Margrethe ^c,e   Pavelka, Karel ^f   Nordström, Dan C ^g   Canhão, Helena ^h   Tomŝiĉ, Matija ⁱ   Van Vollenhoven, Ronald ^b   Gabay, Cem ^j  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f CHARLES UNIVERSITY   (Czech Republic)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

ⁱ UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^j GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

Biologic drugs; Disease activity; Rheumatoid arthritis; Rituximab; Tocilizumab

Indexed keywords

ABATACEPT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISONE; RITUXIMAB; TOCILIZUMAB;

ADULT; ARTICLE; CLINICAL DISEASE ACTIVITY INDEX; DAS28; DRUG EFFICACY; DRUG WITHDRAWAL; EUROPE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE;

EID: 84961950220     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kev297     Document Type: Article

References (21)

1. Finckh A, Ciurea A, Brulhart L et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
2. Emery P, Gottenberg JE, Rubbert-Roth A et al. Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study. Ann Rheum Dis 2015;74:979-84.
3. Finckh A, Möller B, Dudler J et al. Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. Ann Rheum Dis 2012;71:1680-5.
4. Genovese MC, Becker JC, Schiff M et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N Engl J Med 2005;353:1114-23.
5. Cohen SB, Emery P, Greenwald MW et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.
6. Emery P, Keystone E, Tony HP et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
7. Genovese MC, Breedveld FC, Emery P et al. Safety of biologic therapies following rituximab treatment in rheumatoid arthritis patients. Ann Rheum Dis 2009;68:1894-7.
8. Mishra R, Singh V, Pritchard CH. Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis. Rheumatol Int 2011;31:481-4.
9. Chatzidionysiou K, Lie E, Nasonov E et al. Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012;71:374-7.
10. Carpenter JR, Kenward MG. Multiple Imputation and its Application. Chichester: John Wiley & Sons, 2013.
11. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 1998;41:1845-50.
12. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. Rheum Dis Clin North Am 2009;35:745-57.
13. Aletaha D, Smolen JS. The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care. Rheum Dis Clin North Am 2009;35:759-72.
14. Wells GA, Tugwell P, Kraag GR et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol 1993;20:557-60.
15. Kosinski M, Zhao SZ, Dedhiya S et al. Determining minimally important changes in generic and diseasespecific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000;43:1478-87.
16. Gabay C, Emery P, van Vollenhoven R et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
17. Walker UA, Courvoisier DS, Dudler J et al. Do new biologics meet the unmet medical need in rheumatoid arthritis? Safety and efficacy of abatacept following B-cell depletion. Rheumatology 2011;20:243-4.
18. Das S, Vital EM, Horton S et al. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy. Ann Rheum Dis 2014;73:909-12.
19. Finckh A, Ciurea A, Brulhart L et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23.
20. Strand V, Rentz AM, Cifaldi MA et al. Health-related quality of life outcomes of adalimumab for patients with early rheumatoid arthritis: results from a randomized multicenter study. J Rheumatol 2012;39:63-72.
21. Hyrich KL, Watson KD, Silman AJ, Symmons DPM. Predictors of response to anti-TNF-a therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006;45:1558-65.